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Title: MABp1, A Novel Antibody Therapy for Treating Advanced Colorectal Cancer:  A 2:1 1 
Randomized, Double Blind, Placebo-controlled, Phase 3 Study 2 
Background: An antibody (MABp1) targeting interleukin-1α previously demonstrated a 34% disease 3 
control rate and notable recovery from debilitating symptoms such as loss of lean body mass (LBM), 4 
fatigue, pain and anorexia in end-stage patients. Symptomatic improvement from treatment suggested 5 
that these symptom measures may represent a novel way to assess efficacy.  A Phase III study was 6 
thus designed using these criteria to evaluate health status as a means to determine efficacy of the 7 
anti-tumor therapy in patients with advanced disease. 8 
Methods: In this double-blind placebo-controlled randomized phase 3 trial, a central randomisation 9 
scheme with Interactive Web Response System was employed to assign patients (2:1) to receive either 10 
MABp1 or placebo. Patients enrolled had metastatic or unresectable disease, failed oxaliplatin and 11 
irinotecan, ECOG status 1-2, systemic inflammation or weight loss, and other disease-related 12 
morbidities that are poor prognosticators. Patients received 4 bi-weekly i.v. infusions of MABp1 or 13 
placebo at 7.5 mg/kg and were assessed for response. The primary endpoint, Clinical Response Rate 14 
(CRR), was determined for a modified intent to treat population, which included all patients that 15 
received at least one dose of MABp1 or placebo.  CRR was prospectively defined as stable or 16 
increased LBM (measured by Dual Energy X-ray Absorptiometry) and stable or improved health status 17 
in two or three of the categories pain, fatigue and anorexia (reported using EORTC-QLQ-C30) from 18 
baseline to week 8.  [NCT02138422] 19 
Findings:  Patients were randomized between May 20th 2014 and September 2nd 2015.  The study was 20 
completed on November 3rd 2015. The observed CRR for MABp1 treated patients was 68 (33%) of 207 21 
and 19 (19%) of 102 for placebo (relative risk 1.76, 95% CI 1.12-2.76, 1-tailed p=0.0045). The most 22 
common grade 3-4 events were anemia (8 of 207 [4%] vs 5 of 102 [5%]), alkaline phosphatase 23 
increase (9 of 207 [4%] vs 2 of 102 [2%]), fatigue (6 of 207 [3%] vs 7 of 102 [7%]), and AST increase (6 24 
of 207 [3%] vs 2 of 102 [2%]) in MABp1 vs placebo, respectively.  During the 8 week study period 18 25 
patients died in the MABp1 arm (9%) vs 11 (11%) in placebo.  There were no deaths or serious 26 
adverse events related to therapy. There seemed to be a reduction in SAEs in the treatment arm (48 27 
(23%) of 207) versus placebo (32 (31%) of 102) although the difference did not reach statistical 28 
significance (1-tailed p=0.06). 29 
Interpretation: A new symptom-based endpoint was found to be useful in evaluating responses to a 30 
therapy that targets tumor-related inflammation. Using this approach, an antibody derived from human 31 
 3 
immunity against an endogenous mediator of inflammation was shown to provide clinical benefit in 1 
advanced colorectal cancer. 2 
Funding:  XBiotech  3 
 4 
 5 
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Introduction 1 
Colorectal cancer is the second leading cause of malignancy in the industrialized world and the 2 
incidence is increasing with economic development and aging worldwide1. Half of all patients 3 
diagnosed currently will progress and succumb to the disease2. Disease progression is typically 4 
associated with significant morbidities related to the underlying disease process as well as to treatment-5 
related toxicities. In this population, the benefit of further therapy must be weighed against increasing 6 
morbidities and loss of life quality related to the therapy itself. A substantial and growing need therefore 7 
exists for a way to evaluate new anti-cancer agents with respect to their ability to offer unequivocal 8 
clinical benefit during therapy to patients suffering from advanced colorectal and other forms of 9 
cancers.  10 
The European Medicines Agency (EMA) has provided a regulatory path to encourage and expedite the 11 
development of anti-cancer agents that improve patient health status while prolonging life. These 12 
guidelines enable development of anti-cancer agents based on an effect that improves debilitating 13 
symptoms in patients, particularly where the effect is the result of an anti-tumor mechanism and the 14 
clinical measures are considered prognosticators for overall survival3. The current study design was 15 
developed based on this concept in collaboration with the EMA’s Scientific Advice Working Party 16 
(SAWP). 17 
The treatment agent used in the study was a human monoclonal antibody derived from a human with 18 
natural neutralizing antibodies against interleukin-1α (IL-1α). The IL-1 pathway, and specifically IL-1α, 19 
is a highly desirable target for anti-cancer therapy because of its pathological role in both local and 20 
systemic effects of cancer4. IL-1 is a key source of inflammatory signaling in the tumor 21 
microenvironment, where it occurs as a result of malignant cells or infiltrating leukocytes or stromal 22 
cells5. IL-1 can by itself drive varied inflammatory processes, such as COX-2 upregulation, but it also 23 
induces several inflammation-inducing mediators (cytokines/chemokines, matrix-metalloproteinases, 24 
angiogenic factors, etc.), which result in amplification of the inflammatory response and the creation of 25 
a pro-tumor environment. IL-1 activity in the tumor microenvironment is thus implicated in the promotion 26 
of tumor invasiveness and metastasis6,7,8. In addition, IL-1 activity induces expression of adhesion 27 
molecules on endothelial cells, tumor cells and leukocytes and thus increases cell infiltration at sites of 28 
tumors and promotes metastatic spread of the malignant cells. In experimental tumor systems and in 29 
patients, effects of IL-1 activity in the tumor microenvironment with respect to tumorigenesis and tumor 30 
invasiveness (growth, angiogenesis, local spread and metastasis) have been described9,10. The IL-1 31 
pathway also contributes to suppression of anti-tumor immune mechanisms such as immune recruiting 32 
 5 
and activating myeloid-derived suppressor cells (MDSCs) and T regulatory cells11,12. IL-1α and 1 
cytokines it induces, like interleukin-6 (IL-6), cause fever, fatigue, anorexia, and acute phase protein 2 
secretion. IL-1 signaling via the hypothalamus-pituitary-adrenal axis may mediate metabolic pathology, 3 
involving heightened gluconeogenesis and loss of lean body mass (LBM). IL-1-signaling at the site of 4 
muscle can also affect a direct breakdown of muscle tissue. As IL-1 signaling mediates these myriad 5 
local and systemic responses in the context of malignant tumors, neutralization with a monoclonal 6 
antibody was believed to have the potential to antagonize tumor growth and to reverse debilitating 7 
morbidities associated with the disease.  8 
Findings previously reported with the monoclonal antibody therapy in advanced cancer patients 9 
supported this hypothesis13. In the previous study, monotherapy with the antibody was associated with 10 
a 34% disease control rate. Key pharmacodynamic responses were also seen, including normalization 11 
of paraneoplastic thrombocytosis, reduction in metabolic rate and a lowering of systemic inflammation 12 
(serum IL-6 levels)—all measures known to correlate with overall survival in advanced cancer14,15,16. 13 
There was also recovery from key disease related morbidities, including reduction in fatigue, pain, and 14 
anorexia.  Novel observations also included marked gains in LBM. In colorectal cancer, good outcomes 15 
in patients with symptomatic improvement suggested that symptom measures might represent a novel 16 
method to assess treatment benefit in advanced cancer.  A phase III study was designed in order to 17 
confirm these earlier findings.  18 
  19 
 6 
Methods: 1 
Study Design and Participants 2 
The study was conducted at forty-two outpatient oncology clinics in the European Union and Russia, 3 
and was an 8 week, randomized (2:1), double blind, placebo-controlled design.  [NCT02138422] 4 
All patients included in the study were expected to have both metastatic and symptomatic disease. 5 
Furthermore, inclusion criteria focused on symptomatic elements of the disease that correlate with 6 
prognosis. That is, patients were systematically selected with multiple symptoms that portend poor 7 
outcomes. Patients were required to have failed both oxaliplatin and irinotecan in prior regimens for 8 
metastatic disease. Patients were a minimum of 18 years but also included those beyond 70 years of 9 
age. Eastern Cooperative Oncology Group (ECOG) status 0 patients were excluded, with only ECOG 1 10 
or 2 eligible. Disease related morbidities were required and were separated into two domains, to ensure 11 
that patients had evidence of key pathophysiological symptoms that could be measured respectively 12 
through DEXA and self-reported outcomes. Patients were required to have at least one abnormality in 13 
each domain.  14 
Patients were thus required to have either any degree of unintentional weight loss (up to 20%) in the 15 
previous 6 months or serum Interleukin 6 levels ≥10 pg/ml17.  They were also required to have one or 16 
more patient reported symptoms: anorexia, with a score of >10; presence of fatigue, with a score of 17 
>10; presence of pain, with a score of >10; decreased role, emotional and social function, with a score 18 
of < 90. Symptoms were captured using the European Organization for Research and Treatment of 19 
Cancer (EORTC) quality of life questionnaire (QLQ-C30). 20 
Serum chemistries, blood counts and IL-6 levels were required to assess eligibility. There were no 21 
restrictions regarding histologies permitted nor for molecular aberrations, such as KRAS mutation.  22 
Progressive disease was established based upon failure of both oxaliplatin and irinotecan based 23 
regimens, as well as the presence of metastatic or inoperable disease. The estimated life expectancy in 24 
this population is approximately 4.6 months, although this could be less due to exclusion of ECOG 0 25 
patients18.   26 
A two-week washout from previous cancer therapies or from agents used to treat symptoms, such as 27 
corticosteroids or stimulants was mandatory.  Subjects with mechanical obstructions, uncontrolled 28 
medical disorders or dementia were excluded. 29 
 7 
The study was performed in accordance with the declaration of Helsinki and in agreement with the 1 
International Conference on Harmonisation (ICH) guidelines on Good Clinical Practice (GCP).  The 2 
study protocol and all its amendments were reviewed and approved by the appropriate independent 3 
ethics committees and all patients provided written informed consent prior to participation. 4 
An Independent Data Monitoring Committee (IDMC) was established to assess safety of the 5 
intervention at a pre-specified interim analysis, which occurred after 50% enrollment.  The IDMC was 6 
also responsible for recommending adjustments to the sample size based upon the number of subjects 7 
that were not evaluable for the primary endpoint at the interim safety analysis. 8 
Randomisation and Masking 9 
The study employed a non-stratified randomisation plan.  A central randomisation scheme with 10 
Interactive Web Response System (IWRS) was employed to facilitate effective randomisation and 11 
allocation concealment. The scheme used a block randomisation technique, randomly assigning 12 
participants within blocks (block size 6) based on a 2:1 allocation ratio to MABp1 or placebo. The 13 
randomization sequence was generated using Oracle Clinical (OC) Remote Data Capture (RDC) 14 
application (Oracle Corporation, Redwood City, CA USA).  When a patient was randomized by the site 15 
investigator, the RDC generated a unique randomization sequence number (randomization code). The 16 
randomization code and the study arm assignment were safely retained in the backend of the OC 17 
database.  The contract drug distribution organization had one-time access to download the un-blinded 18 
list for the purpose of labeling and shipping of the study drugs. The patients, investigators, the Clinical 19 
Research Organization (CRO), and the sponsor were blinded to treatment allocation until after 20 
completion of the study and database lock. 21 
 22 
Procedures 23 
Patients were randomized to treatment with antibody (7.5 mg/kg) plus best supportive care (BSC) 24 
versus placebo plus BSC, with intravenous administration every two weeks for a total of 8 weeks (4 25 
doses).  BSC did not include any agents with proven anti-cancer effect or other agents that might 26 
conceivably confound measurement of the primary endpoint, such as corticosteroids, megestrol acetate 27 
or stimulants.  No information was collected on subsequent anti-neoplastic therapy that patients 28 
received after coming off study either during the 8 week study period or in the extension period, as this 29 
would not affect the primary endpoint assessment which occurred at 8 weeks. 30 
 8 
Patient welfare was paramount to study design. The study was thus conceptualized in a manner that 1 
would provide the potential for all patients in the study to receive antibody therapy and further, to allow 2 
patients to continue on therapy as long as they were deemed to be benefiting. After completion of the 3 
scheduled 8 week treatment regimen, all patients from either arm were eligible to receive MABp1 in an 4 
open label extension phase of the study. Treatment allocation from the 8 week study period was not 5 
revealed after completion of the study, therefore neither patients nor caregivers were aware whether 6 
patients entering the open label extension were transferring from placebo or merely staying on active 7 
drug.  Assessment of primary and secondary endpoints were based on data collected during the 8 8 
week study period.  There were no further prospective assessments of efficacy in the open label 9 
extension, where study visits included only safety assessment.  The open label extension is still 10 
ongoing. 11 
During the 8 week study period, tumor assessments, DEXA scans, and administration of the EORTC 12 
questionnaire were performed at baseline, prior to dosing, and again at 8 weeks of therapy.  Patients 13 
were assessed for adverse events and had routine laboratory assessments (chemistries and 14 
hematology) every 2 weeks.  Patients were required to discontinue therapy for any adverse event of 15 
grade 3 or greater with a relationship assessed by the investigator of probably or definitely related to 16 
study therapy, or any clinical adverse event, laboratory abnormality or concurrent illness, which in the 17 
opinion of the investigator, indicated that continued participation in the study was not in the patient’s 18 
best interest.  There were no requirements for dose modifications, however doses could be delayed for 19 
up to 7 days in the event of adverse events that were not related to study drug administration. 20 
DEXA is an imaging modality used to determine the mass (in grams) of bone, fat and lean body 21 
compartments19. DEXA is an accurate and precise method for measuring body composition, with a 22 
coefficient of variation for serial measurements of LBM between 0.4% and 1.3%20.  Analysis of DEXA 23 
images was performed by a central imaging vendor. A board certified radiologist, blinded to treatment 24 
allocation, was responsible for reviewing DEXA images for artifacts and confirming correct placement of 25 
cut-lines, and the plausibility of the calculated numbers.   Patients were scanned with the same DEXA 26 
machine using the same software version, at both screening and week 8.  The use of IV or oral contrast 27 
was restricted within 14 days of receiving the baseline or follow up scan. 28 
Tumor measures were performed using CT or MRI imaging within four weeks prior to dosing and after 8 29 
weeks from first treatment.   No additional radiologic assessments were performed after week 8.  30 
Tumor assessment was performed by a board certified radiologist at a central vendor, blinded to 31 
treatment allocation, utilizing RECIST guidelines (v1.1).   32 
 9 
The EORTC QLQ-C30 questionnaire (version 3) is a validated quality of life instrument for assessment 1 
of cancer related symptoms.  It consists of 30 items that encompass 3 symptom scales (pain, fatigue, 2 
and nausea/vomiting), 6 single-item symptom items, 5 functional scales (physical, cognitive, role, 3 
emotional, and social), and one scale assessing global health status/quality of life. Each scale consists 4 
of 2-5 items.  All items have four response categories (not at all, a little, quite a bit, and very much), 5 
except for 2 items assessing overall health status/quality of life, which use a seven-point scale. 6 
Outcomes 7 
Clinical response rate (CRR), as defined in the protocol, was a composite endpoint that involved 8 
measuring body compartments (to determine lean body mass (LBM)) using dual energy X-ray 9 
absorptiometry (DEXA), and the use of the EORTC-QLQ-C30 instrument to assess patient reported 10 
outcomes with respect to fatigue, pain and anorexia from baseline to week 8. Patients had to maintain 11 
or improve LBM and maintain or improve in regards to two-of-three of the categories of pain, fatigue 12 
and anorexia  (Figure 1). The clinical response endpoint was prospectively designed as part of the 13 
Scientific Guidance procedure with the EMA. The combination of the novel but objective DEXA 14 
measurement together with the established but self-reported measures of health status were deemed 15 
to be a compelling assessment of clinical performance. These measures were thus combined to create 16 
a composite endpoint that was a direct measure of clinical benefit and one that was expected to 17 
correlate with overall survival.  CRR was not re-assessed during the open label extension. 18 
Evaluation of secondary endpoints was planned to compare treatment versus placebo groups as a 19 
whole largely as a measure of drug safety during the 8 week study period. To further elucidate the 20 
relevance of the prospective clinical response criteria on an exploratory basis, secondary measures 21 
were also examined to further fully characterize the nature of the prospective clinical response. 22 
Secondary measures were as follows: EORTC QLQ-C30 for functional performance (role, work and 23 
social functions); global quality of life (QoL); adverse and serious adverse events; tumor response 24 
(RECIST); paraneoplastic thrombocytosis; and systemic inflammation.  25 
The study design does not enable a comparison of overall survival between treatment arms. The 26 
fundamental concept of the study was to establish a clinical response endpoint that could evaluate 27 
treatment efficacy rapidly enough to reasonably allow for all patients to have access to active treatment. 28 
On recommendation of the study chair, the protocol was amended as of November 20th, 2014 to follow 29 
up patients for survival as a measure of safety.  Approximately one third of patients had discontinued 30 
treatment by the time the amendment came into effect.  The availability of overall survival data provided 31 
 10 
the opportunity for post hoc survival analysis of outcomes for clinical responders as defined by the 1 
primary endpoint. 2 
Other secondary measures involved assessment of pharmacodynamic responses to IL-1 antagonism, 3 
particularly those related to disease pathophysiology. Parameters measured were thus change in 4 
systemic inflammation as reported by serum IL-6 levels as well as assessment of paraneoplastic 5 
thrombocytosis. Univariable analysis was performed to evaluate the assumption of normality. Tukey’s 6 
3-inter-quartile range (IQR) method of determining outliers was used as a guides21.  To make the range 7 
more expansive (that detects more extreme values), we replaced IQR range with the range between 8 
5th and 95th quantile. Values higher than 3 times this range were considered extreme outliers. 9 
Testing for hematologic parameters, including platelets and serum IL-6 levels, was performed at 10 
screening, and subsequently every two weeks at each dosing visit.  Platelet counts were determined by 11 
a central laboratory using automated cell counters.  Serum IL-6 levels were measured at XBiotech with 12 
a commercially available ELISA kit from eBioscience (catalog # 88-7066).  An analysis of covariance 13 
(ANCOVA) statistical model was used to assess both change in IL-6 levels and platelet counts. The 14 
response in terms of IL-6 decrease was determined at last visit compared to baseline. A relative 15 
change of <25%, computed as [(post-pre)/pre], was considered a decrease in IL-6.  16 
Safety was assessed by comparing the incidence of serious adverse events (SAEs) and adverse 17 
events (AEs) between groups during the 8 week study period and classified according to the National 18 
Cancer Institute Common Terminology Criteria for Adverse Events (v4.03) (CTCAE). Assessment of 19 
SAEs included all adverse events, which included events related to underlying, cancer related 20 
progression.  Assessment of AEs and laboratory examinations occurred every two weeks while on 21 
study.  22 
Statistical Analysis 23 
The trial was designed to have 80% power to detect 20% effect size, with one-sided alpha of 0.0125 24 
and 2:1 allocation ratio. The alpha level was set to 0.0125 in order to account for the two-component 25 
composite endpoint.  26 
The primary efficacy analysis was conducted on a modified intent-to-treat population. As defined in the 27 
protocol, this population included only those subjects who had been randomised and received at least a 28 
single dose of therapy. Patients missing primary endpoint data, and patients that received restricted 29 
therapies were considered non-responders. 30 
 11 
The initial sample size was 276, which factored in a 5% drop-off rate. During the planned interim review 1 
of safety data, the IDMC recommended increasing the oversampling to 20% to account for patients with 2 
missing endpoint data. 3 
The primary endpoint was compared between the MABp1 and placebo arms using Pearson chi-square 4 
test. Relative risk and unadjusted odds ratio estimates are presented with 95% confidence intervals 5 
(95% CI). Accounting for the two components of the composite endpoint, 1-tailed type I error of 0.0125 6 
was used for determining statistical significance of the primary outcome.  7 
Paraneoplastic thrombocytosis and systemic inflammation were assessed using analysis of covariance 8 
model (SAS GLM procedure), with classification groups (treatment arm and overall response status) as 9 
factor and baseline value as covariate. The difference in least-square means (LS Means) and 2-sided P 10 
values derived from analysis of covariance model were presented for comparison.  11 
A sensitivity analysis was performed on the primary endpoint, stratified by ECOG status, gender, 12 
geographically and KRAS mutation status. 13 
 14 
Clinical sites followed-up patients after study completion or discontinuation and assessed their survival 15 
status. An analysis was performed to assess overall survival and a log-rank test was used for 16 
comparing between groups. Survival was assessed for all patients that entered the study after the 17 
November 2014 protocol amendment, which enabled collection of survival data.  Survival duration was 18 
defined as time from first study drug administration to date of death. Patients event-free at the last 19 
follow-up time point were censored.  Patients that went off study prior to the protocol amendment, were 20 
lost to follow up or who withdrew consent were not included in survival analysis. Univariate Cox model 21 
was used for evaluating the association of the grouping variable and computing hazard ratio (HR). 22 
Hazard ratio along with 95% confidence intervals (CI) from the Cox model is reported in the result. 23 
Significance was tested at 2-sided p of 0.05. SAS 9.3 (SAS Institute Inc., Cary, NC) was used for 24 
statistical analysis. 25 
[NCT02138422] 26 
 27 
Role of the funding source: 28 
The sponsor provided the study drug.  The study chair (TH), in collaboration with the sponsor, 29 
developed the protocol and this report and were responsible for conduct of the study.  The sponsor 30 
performed data collection.  Data review and analysis was performed by the sponsor and TH, who had 31 
 12 
access to the study data.  An independent data monitoring committee was responsible for unblinded 1 
assessment of safety data.   2 
 3 
Results 4 
Patients 5 
Findings were based on a total of 458 patients screened, 333 randomized, and 309 receiving at least 6 
one dose of therapy between May 20th, 2014 to November 3rd, 2015 (See Figure 2, flow chart showing 7 
the patient disposition). The median follow-up duration in the 8 week blinded study period for MABp1 8 
and placebo patients was 49 (IQR 48-50) days and 49 (IQR 48-51) days respectively. The 8 week 9 
study period ended after completion of the last patient, last visit, however an open label extension is still 10 
ongoing.  A total of 202 patients continued in the open label phase of the study and received the active 11 
therapy. This included 140 (68%) of 207 patients from treatment and 62 (61%) of 102 patients from 12 
placebo arms. 13 
The demographic and baseline characteristics were well balanced between the arms. Comparison of 14 
important variables did not show any statistical difference (age p=0.53, sex p=0.54, ECOG p= 0.45, 15 
prior antineoplastic medications p= 0.26, body weight p=0.37) (Table 1).  The KRAS status of tumors 16 
was analyzed and showed no imbalance in distribution between arms. BRAF mutation status was not 17 
however captured and therefore the distribution between study arms is not known, although this could 18 
have been informative.  19 
There were no differences in corticosteroid (placebo, 1 of 102; MABp1, 1 of 207) or megestrol acetate 20 
(placebo 0 of 102; MABp1, 1 of 207) use between patients in either the MABp1 or placebo arms, and 21 
no patients that received these agents were responders.  In the open label extension 24% (49 of 202) 22 
of patients received corticosteroids.  Usage of corticosteroids in the open label did not change the AE 23 
profile, which suggests that the combination is safe.  It is not possible to assess the effect of steroids on 24 
the efficacy of MABp1 as no endpoint data was collected during the extension. No patients received 25 
anti-neoplastic therapies in the 8 week study or the open label extension. 26 
Efficacy 27 
 13 
A clinical response was prospectively defined as a co-primary measure, which included (1) lean body 1 
mass as measured by dual energy X-ray absorptiometry; and (2), the EORTC categories pain, fatigue 2 
or anorexia. Demonstration of a statistically significant enhancement in rate of clinical responses in the 3 
treatment arm versus the placebo was considered a successful primary outcome. The primary efficacy 4 
analysis was performed in the 309 patients (207 MABp1 and 102 placebo) who received at least one 5 
dose of therapy. The per-protocol population, excluding patients who discontinued therapy prior to 6 
week 8 assessment, consisted of 169 MABp1 and 83 placebo patients. 7 
The MABp1 therapy arm had a significant improvement in CRR compared to placebo. As shown in 8 
Table 2, patients demonstrated significantly higher CRR with respect to placebo (33% and 19%, 9 
relative risk 1.76 (95% CI 1.12 to 2.76, one-tailed p=0.0045)).    10 
Efficacy analysis in the per-protocol population also demonstrated significant improvement in the 11 
composite primary endpoint in MABp1 patients: 68 (40%) of 169 MABp1 and 19 (23%) of 83 placebo 12 
subjects were responders (relative risk 1.76, (95% CI 1.14 to 2.72, one-tailed p= 0.0033)). 13 
There were 5 (4.9%) of 102 patients in the placebo group who received restricted therapy and were per 14 
protocol non-responders. In MABp1 and placebo arms 52 (25%) of 207 and 29 (28%) of 102 were per 15 
protocol non-responders for disease progression or missing data (p=0.53). 16 
A sensitivity analysis was performed on the primary endpoint, stratified by ECOG status, gender, 17 
geographically and KRAS mutation status. The results were consistent with the benefit observed in the 18 
overall MABp1 group (Table 3). Response on individual components of the primary endpoint, i.e. LBM, 19 
pain, fatigue, and appetite, did not show any difference between groups (Table 5) 20 
Secondary 21 
Change in platelet count and IL-6 level were significantly different between treatment and placebo arms 22 
(Table 4). There was a worsening of paraneoplastic thrombocytosis after 8 weeks, with placebo 23 
patients exhibiting increased platelet counts compared to those receiving antibody therapy (40±8 vs 24 
14±5, 1,000 per mm3, p = 0.0052). Placebo patients were found to have elevated systemic 25 
inflammation compared to the active treatment group as measured by serum IL-6 (LS means 9.9±2.7 26 
vs 1.6±1.9 pg/ml, p=0.012). Baseline EORTC response was available for 309 patients, and week 8 27 
EORTC response was available for 241 patients (79 (77%) of 102 Placebo, MABp1 162 (78%) of 207 28 
MABp1, p=0.87.  In the majority of cases, the reasons for the absence of completed questionnaires 29 
were for patients coming off study early due to disease progression, and hence they did not complete 30 
 14 
the questionnaire. 1 
Results from covariance analysis for change in EORTC scores showed no difference between arms. To 2 
examine if possible asymmetric distribution of EORTC scores affects the covariance analysis, we re-3 
analyzed the EORTC measures using a mixed model with restricted maximum likelihood (REML) 4 
variance component and the results were not different. Assessment of univariate normality of change in 5 
IL-6 identified four extreme observations. Three times of 5th and 95th quantile range was 222 mg/ml; 6 
the outlying observations reported a change of 275, 746, 1216, and 10176 mg/ml. These four 7 
observations were removed from analysis. The univariate analysis of the platelet count did not 8 
demonstrate any significant asymmetry; the skewness and kurtosis were within acceptable range of 9 
normal univariate distribution (see web appendix p7). 10 
Change in other markers of inflammatory response, such as platelet-lymphocyte ratio (PLR), neutrophil-11 
to-lymphocyte ratio (NLR) and CRP were evaluated. The baseline NLR and PLR were well balanced 12 
between MABp1 and placebo arms (NLR 4.6±2.7 and 4.5±3.2 (p=0.87), PLR 196±90 and 207±139 (p= 13 
0.42) respectively). Average change at 8 weeks in NLR was 0.78 (95% CI 0.36 to 1.19) in MABp1 and 14 
1.1 (95% CI 0.55 to 1.65) in placebo, p= 0.35. Similarly no significant change in PLR was observed; 15 
average change 41 (95% CI 17 to 66) in MABp1 and 26 (95% CI 10 to 43) in placebo, p= 0.32. With the 16 
high variability in the CRP level, detecting statistical significance was not possible. 17 
Computed tomography analysis for tumor response based on RECIST criteria showed that after 4 18 
cycles of therapy, 35 (17%) patients in the treatment arm had stable disease (SD) compared to 12 19 
(12%) patients in the placebo arm. These findings suggested an increased risk of disease progression 20 
in the placebo arm compared to the treatment arm (HR 1.26 (95 CI 0.93-1.70, p=0.14). There were no 21 
significant differences between arms with respect to patient reported outcomes. 22 
Post hoc Analysis 23 
The primary endpoint was a composite measure of performance with respect to lean body mass and 24 
pain, fatigue and anorexia. The break-out of the performance for each of the components measured for 25 
this clinical response endpoint showed that the responders indeed exhibited substantial and significant 26 
improvement in key individual measures for health status. The 87 patients who met the prospective 27 
definition for clinical response criteria showed robust improvement for lean body mass (1.4±1.3, median 28 
1.1, kg), as well as reduction in fatigue (-10.85±22.9 [median -11.0]) and pain (-12.66±23.3 [median -29 
16.0]) (Table 6). Appetite improved significantly on average but there was no median change (-30 
 15 
13.80±27.7 [median 0.0]). The changes presented above are the absolute change from baseline. We 1 
also calculated the LS mean change after adjusting for baseline values and presented the findings by 2 
clinical response status in Table 6. Post hoc analysis further demonstrated that clinical response was 3 
prognostic for overall survival as well as for improvement with respect to all other endpoints, including 4 
clinical, laboratory, radiologic and patient reported outcomes. Survival data was available for 175 5 
patients (126 of 222 (57%) non-responders and 49 of 87 (56%) responders). At the last follow-up 110 6 
(87%, 95% CI 81 to 92%) non-responders and 25 (51%, 95% CI 38 to 66%) responders had died (log-7 
rank p <0.001). The median survival was 4.2 (95% CI 3.2 to 5.3) months and 11.5 (95% CI 8.3 to 13.2) 8 
months for non-responders and responders respectively (see web appendix p5). Overall survival was 9 
also compared between the study arms. Survival data was available for 59 placebo patients and 116 10 
MABp1 patients.  At the follow-up, 42 (71%, 95% CI 59 to 82%) of placebo patients compared to 93 11 
(80%, 95%CI 73 to 87%) of MABp1 patients had died (log-rank p=0.25, HR 0.81 (95% CI 0.56 to 1.16). 12 
The median survival was 6.3 (95% CI 4.1 to 8.9) months and 6.1 (95% CI 4.4 to 7.2) months for 13 
placebo and MABp1 arms respectively (see web appendix p6).  14 
Clinical response was significantly associated with lower death (hazard ratio 0.31, 95% CI 0.20 to 0.48, 15 
p<0.0001). Moreover, subjects achieving response criteria had a significant reduction in the incidence 16 
of SAEs due to any cause (29.3% [65 of 222] vs 5.7% [5 of 87], p<0.0001) compared to non-17 
responders.  Patients that experienced a clinical response were also more likely to achieve stable 18 
disease (RECIST V1.1) (24.1% [21 of 87] vs 11.7% [26 of 222]; p=0.0062) at the week 8 endpoint.  19 
A similar effect was observed when stratified based on EORTC self-reported symptoms and global QoL, 20 
and pharmacodynamic endpoints (see web appendix p4). Response to these measures was 21 
prognostically associated with overall survival. However, the survival benefit associated with the clinical 22 
response endpoint appeared to be stronger than the individual measures. This prompted an analysis to 23 
assess if any additive interaction existed between the components of the primary endpoint, i.e. DEXA 24 
and EORTC measures.  We used a multivariate Cox model to assess the additive interaction and also 25 
calculate the relative excess risk due to interaction (RERI). Interaction term for DEXA and EORTC 26 
symptoms was observed on the additive model (p=0.043). This indicated that the joint effect captured in 27 
the primary endpoint was stronger than that of the individual component measures.  28 
Secondary measures improved among the prospectively defined clinical responders (see web appendix 29 
p2). A reduction was seen in serum IL-6 levels (-3.38±6.31 pg/ml vs 10.3±2.2 pg/ml) and there was an 30 
increase in paraneoplastic thrombocytosis in the non-responder group (median change 23,000/mm3, 31 
IQR -11,000 to 60,000), while platelet counts decreased in responders (median -11,000/mm3, IQR -32 
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38,000 to 39,000) (ANCOVA analysis showed change was statistically significant (p=0.00017)).   1 
Patient functional performance and global quality of life (QOL) also showed marked improvements in 2 
responders versus non-responders: QOL (4.32 vs -6.98, p=<0.0001); role function (3.87 vs -13.43, 3 
p=<0.0001); emotional function (10.03 vs -2.33, p<0.0001); and social function (10.16 vs -6.71, 4 
p<0.0001). 5 
Safety 6 
The most common AEs reported (>10%) were abdominal pain, peripheral edema, fatigue, anemia, 7 
constipation, decrease in weight, asthenia, decreased appetite, and nausea. A total of 159 patients 8 
receiving experimental therapy and 79 patients receiving placebo had at least one adverse event. The 9 
majority of these events were grade 1 or 2, and appeared to be related to the underlying CRC. The 10 
prevalence of AEs was similar in treatment and placebo groups (Table 7). The incidence of SAEs in the 11 
placebo arm compared to treatment arm was 33 (32%) and 47 (23%) respectively (p=0.07).  12 
The most common grade 3-4 events were anemia (8 of 207 [4%] in the MABp1 arm vs 5 of 102 [5%] in 13 
placebo), alkaline phosphatase increase (9 of 207 [4%] in MABp1 vs 2 of 102 [2%] in placebo), fatigue 14 
(6 of 207 [3%] in MABp1 vs 7 of 102 [7%] in placebo), and AST increase (6 of 207 [3%] in MABp1 vs 2 15 
of 102 [2%] in placebo).  There were no deaths related to therapy.  One patient discontinued therapy 16 
due to an upper extremity DVT, which occurred one week after study drug administration.  This event 17 
was assessed as probably related by the investigator, but not related by the sponsor based on analysis 18 
of similar events. 19 
During the 8 week study period, 18 patients died in the MABp1 arm (9%) vs 11 (11%) in placebo.  20 
There were no deaths related to therapy, and all appeared to be related to the patient’s underlying 21 
disease.  The event terms reported for the deaths by arm are as follows: 22 
• Placebo causes of death:  Anemia (1); disease progression (2); dyspnea (1); renal failure(1); 23 
liver failure (1); respiratory failure (1); death* (2); general health deterioration (1); and 24 
thromboembolic event (1). 25 
• MABp1 causes of death:  disease progression (5); CNS metastasis (1); obstruction (1); hepatic 26 
failure (1); condition aggravated (2); renal impairment (1); ileus (1); peritonitis (secondary to 27 
surgical complication) (1); dehydration (1); respiratory failure (1); hip fracture (1); death* (1); and 28 
cardiopulmonary failure (1). 29 
*Died at home after coming off study, presumed to be disease progression 30 
 31 
 17 
Discussion 1 
A monoclonal antibody targeting the potent inflammatory cytokine IL-1a was derived from a natural 2 
human immune response and used to block tumor-related inflammation in advanced colorectal cancer 3 
patients. Earlier findings in advanced cancer patients suggested anti-neoplastic effects of antibody 4 
monotherapy, including unique observations of resolution of disease-related morbidities. Clinical 5 
responses seen were expected to have strong prognostic value and to be useful as novel endpoints to 6 
evaluate therapy. 7 
In the present study, a composite primary endpoint consisting of radiological and patient self-reported 8 
outcomes was thus used to assess morbidities associated with disease progression in patients with 9 
advanced symptomatic colorectal cancer. Subjects that were stable or improved over an 8 week study 10 
period with respect to the composite endpoint were considered to have a favorable disease course and 11 
prognosis. Patients from either treatment or placebo arms meeting the endpoint criteria would be 12 
considered responders while those with progression would be considered non-responders. The study 13 
was powered to show a significant enhancement in responder rate for subjects receiving MABp1 14 
monotherapy versus placebo. 15 
The primary finding of the study was a significant increase in the number of responders for subjects 16 
receiving antibody monotherapy versus placebo (relative risk 1.76, p=0.0045). Pharmacodynamic 17 
measures of MABp1 activity—systemic inflammation and thrombocytosis—were secondary endpoints 18 
of the study. A significant reduction in systemic inflammation (Serum IL-6, LS means 1.6±1.9 vs 9.9±2.7 19 
pg/ml, p=0.012) and thrombocytosis (platelet count, 14±5 vs 40±8 (x 1,000/mm3), p = 0.0052) was seen 20 
in the treatment group compared to placebo. The findings confirmed that MABp1 monotherapy 21 
rendered significant clinical benefit to patients with advanced colorectal cancer. 22 
Inflammation has long been recognized as a central feature in malignancy, both in the transformation 23 
process but also in creating a pro-tumor microenvironment rich in essential remodeling and angiogenic 24 
factors22,23,24. Efficacy and conversely treatment failure with cytotoxic chemotherapy may also be 25 
explained in part by the impact these agents have of inflammatory mechanisms that affect the tumor 26 
microenvironment25. While the role of inflammation is well established, a targeted anti-inflammatory 27 
approach to the treatment of cancer has yet to yield an approved therapy.  28 
A novel endpoint developed in collaboration with the SAWP was established based on the earlier 29 
findings where systemic improvements in patients were seen from therapy. Patient self-reporting and 30 
objective radiological imaging used in a combined endpoint was expected to provide as a crucial 31 
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measure of health status, and to serve as an important metric of underlying disease progression. Even 1 
though the novel endpoint was not a validated surrogate for overall survival, since the endpoint 2 
provided an unequivocal measure of clinical benefit, successful outcome of the double-blind placebo 3 
controlled study was considered to be suitable for registration. 4 
Symptom-based measures have been used in the development of an anti-cancer agent26. 5 
Nevertheless, a misconception is that an outcome based on symptoms, even if those include objective 6 
radiological measures, would be more suited for assessing palliative therapy. To clarify the importance 7 
and relevance of the primary endpoint with respect to patient outcomes, we performed detailed post 8 
hoc evaluation of subjects that achieved the prospectively defined response criteria.  9 
In the post hoc analysis we undertook a complete deconstruction of the clinical response criteria, 10 
separately evaluating individual components of the prospectively defined combined endpoint, as well as 11 
all other measures, with respect to responders and across study arms. Since the response criteria 12 
required only stabilization or improvement in symptoms, importantly this additional analysis 13 
demonstrated the positive magnitude of change with respect to component measures: responders had 14 
significant gains in lean body mass (1.41±1.3 kg); and clinically significant reductions in fatigue (-15 
10.85±22.9), pain (-12.66±23.3) and anorexia (-13.80±27.7) were associated with the endpoint. The 16 
changes were highly significant in the ANCOVA analysis (Table 6). Moreover, patients meeting clinical 17 
response criteria improved with respect to virtually every other measure of anti-tumor activity evaluated 18 
in the study, including: 5-fold reduced incidence of SAEs (p<0.0001); two-fold increase in likelihood of 19 
stable disease at 8 weeks (p=0.0062); and a median overall survival of 11.5 versus 4.2 months (HR 20 
0.31, 95% CI 0.20 to 0.48, p<0.0001).  Results from ANCOVA model comparing least squares mean 21 
change, adjusted for baseline values, are presented in Table 6.  22 
Another fundamental observation to come from this post hoc analysis was the finding that neither 23 
EORTC nor DEXA measures alone revealed significant differences between arms. These endpoints 24 
could not individually therefore serve as a measure of treatment response. These findings confirmed 25 
that the combination of radiological and self-reported measures used as the primary endpoint were in 26 
fact crucial in identifying patients that were experiencing clinically important recovery or treatment 27 
responses to therapy.  28 
 29 
The clinical response endpoint has thus offered new perspective on the natural history of colorectal 30 
cancer. With nineteen percent of placebo patients achieving the response criteria, this finding suggests 31 
that even in advanced disease, compensatory responses to tumors, likely in part involving 32 
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immunoregulatory mechanisms, can and do still operate to facilitate recovery from debilitating 1 
symptoms and even control progression of the underlying disease process. With this in mind, it should 2 
be emphasized that the therapeutic agent used in the study was an antibody isolated from a natural 3 
immune response. While a great deal of attention has been given recently to the possible role for 4 
enhancing cell mediated immunity to treat cancer, less focus has been given to the potential for 5 
augmenting humoral immunity to fight the disease. The presence of natural anti-tumor and 6 
immunomodulatory antibodies in human plasma has been documented for some time27,28,29. This study 7 
represents the first evidence that these antibodies can be useful as therapeutic agents in cancer. 8 
Findings presented here represent the first evidence that antibodies produced as a result of natural 9 
humoral immunity can play a role in regulating disease progression in human cancer. Investigating the 10 
nature of the clinical responses seen in the placebo subjects, specifically whether these responses 11 
were related to endogenous humoral immunity, was beyond the scope of the study. We did, however, 12 
confirm that responses in placebo patients were not the result of endogenous anti-IL-1a antibody 13 
responses (Data not shown). This raises the possibility that endogenous humoral responses may be 14 
regulating disease progression in placebo patients that showed positive clinical courses and that the 15 
antibody repertoire in such subjects, if investigated in other studies, might be future sources for 16 
additional candidate therapeutic antibodies. 17 
The clinical response criteria used in the study has a number of advantages compared to traditional 18 
endpoints. Overall survival studies require large studies and typically long follow-up times. Moreover, 19 
there is considerable patient variability in OS outcomes in advanced stage treatments as a result the 20 
heterogeneity of patient populations with respect to prior and subsequent therapies30.  Clinical 21 
response criteria evaluated here enable rapid assessment of treatment effect. Sample sizes and study 22 
durations using the clinical response criteria are relatively modest, reducing the time and cost of 23 
development for new agents. The clinical response endpoint also provides an assessment of patient 24 
trajectory after only 8 weeks of therapy, such that patients can be maintained on monotherapy versus 25 
placebo for the duration of the endpoint assessment, and further enabling a crossover of all patients to 26 
active therapy (which in our experience is a paramount consideration to patient welfare). Finally, the 27 
clinical response endpoint is itself a direct measure of crucial aspects of health status, making 28 
treatment response an unequivocal measure of patient benefit.  29 
The study design is not without limitations. The responder analysis used is not a traditional endpoint in 30 
oncology studies, thus exploring and communicating the value of the endpoint with respect to patient 31 
outcomes will require further efforts. While the primary endpoint correlates with substantial overall 32 
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individual survival benefit, it is at present difficult to translate the treatment response rate into a 1 
customary overall survival expectation for the entire treatment population. The present study involved a 2 
relatively small sample population and due to the advanced nature of the subjects enrolled, all patients 3 
could not be factored into the endpoint analysis due to disease progression. Since the outcome of the 4 
study is binary—patients are either responders or non-responders—patients failing to reach the 8 week 5 
endpoint were necessarily considered non-responders. The addition of non-responders to each arm is 6 
dilutive of the potential treatment effect, making it more difficult to achieve significance of the primary 7 
endpoint. The effect of this difficulty was highlighted with the relatively strong performance with respect 8 
to analysis of the per protocol population, where 68 (40%) of 169 MABp1 and 19 (23%) of 83 placebo 9 
subjects achieved clinical responses (95% CI 1.14 to 2.72, one-tailed p= 0.0032). 10 
The concept behind the primary endpoint was to establish means of evaluating a targeted cancer 11 
therapy using a direct and critical measure of clinical benefit. Patients achieving the primary endpoint in 12 
the study had markedly improved overall survival, relatively stable tumor burden and dramatically 13 
reduced incidence serious adverse events. Similar to tumor response measures, however, the ability to 14 
extrapolate response rates to the entire treated population with respect to overall survival benefit will 15 
vary depending on a number of factors, including the durability of the treatment effect, type and 16 
phenotype of the targeted tumor, stage of disease and the use of post progression therapy. 17 
A large global Phase III study for MABp1 monotherapy is ongoing in colorectal cancer with overall 18 
survival as the primary endpoint. It is also considered that MABp1 may work to improve efficacy of 19 
cytotoxic chemotherapy, where disease progression may in part be related to the induction of 20 
inflammation and angiogenic factors in the tumor microenvironment31,32. These combination studies 21 
with MABp1 are currently being planned. 22 
A first-of-a-kind therapeutic antibody derived from natural human immunity has been used to treat 23 
advanced colorectal cancer. Monotherapy with the antibody was intended to augment endogenous 24 
immunoregulatory mechanisms in patients to help antagonize the chronic inflammatory process 25 
involved in tumor growth and disease progression. A novel endpoint used recovery of debilitating 26 
symptoms to evaluate anti-tumor activity of the therapy. The finding of significant response to therapy 27 
offers a highly innovative new approach to treat advanced cancer. 28 29 
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Research in context 3 
Evidence before this study: 4 
Prior to initiation of the pivotal phase 3 trial, an extensive literature review was performed to assess the 5 
validity of functional and metabolic parameters as measures of clinical outcomes and prognosis for 6 
overall survival in advanced cancer patients.   7 
Results for lean body mass were obtained by searching PubMed for: [lean body mass] [prognosis] 8 
[advanced cancer] [survival].  With the exception of the previous trial utilizing MABp1 in advanced 9 
cancer, no trials were identified that showed an improvement in lean body mass or a correlation with 10 
changing lean body mass and survival.  11 
The following terms were used to investigate the EORTC questionnaire:  [EORTC QLQ C30] 12 
[Improvement] [survival] [prognosis].  After filtering results for the previous 5 years, 21 articles were 13 
found.  Several studies were identified, for multiple tumor types, which showed that baseline results in 14 
global QoL, symptoms, and functional domains were prognosticators for survival.  Further, these 15 
studies showed that worsening of these domains with treatment was predictive for worse survival.  16 
Finally, there were reports of studies evaluating changes in EORTC domains during treatment for tumor 17 
types, including prostate, NSCLC, ovarian, hepatocellular, and colorectal cancer.  These trials revealed 18 
that improvement in global QoL, and domains such as cognitive function, physical function, emotional 19 
function, social function, were all associated with prolonged survival. 20 
Finally, the contribution of IL-6 levels and platelet counts were searched.  The following pubmed search 21 
terms were used to investigate IL-6:  [interleukin-6 level] [prognosis] [advanced cancer] [survival].  The 22 
effects of platelets were assessed by searching pubmed for: [platelets] [prognosis] [advanced cancer] 23 
[survival].  Numerous reports were found for both searches which showed a correlation between 24 
elevated IL-6 levels and platelet counts and survival for several tumor types, including pancreatic, 25 
endometrial, ovarian, gallbladder, hepatocellular, non-small cell lung cancer, gastric, renal, and 26 
colorectal cancer.     27 
Added value of this study: 28 
 23 
Extensive prior work has been performed examining the relationship of key functional and metabolic 1 
parameters and their significance in predicting survival outcomes for patients with refractory 2 
malignancies.  The majority of this work has focused on the prognostic value of baseline results of the 3 
EORTC QLQ C30, IL-6 levels, and platelet levels.  However, improvement in QoL and functional 4 
domains, as measured by the EORTC instrument, with treatment has also been shown to predict 5 
prolonged survival.  Less evidence surrounding lean body mass change was found, presumably 6 
because there are no agents that have demonstrated the ability to increase lean body mass in cancer.   7 
The results from the current study show an improvement in a co-primary endpoint of lean body mass 8 
change and symptoms as assessed by the EORTC QLQ C30 questionnaire in patients with refractory 9 
colorectal cancer and disease associated symptoms.  A response as assessed by this co-primary 10 
endpoint, was also associated with improvement in global QoL and functional domains, as well as 11 
reduction in IL-6 levels and stabilization of platelet counts.  These results validate this novel endpoint as 12 
an important measure of clinical benefit in patients with refractory disease, and based on prior research, 13 
suggest that this endpoint is a surrogate for overall survival benefit. 14 
Implications of all the available evidence: 15 
Patients with refractory cancer, who are suffering from disease related symptoms, have few available 16 
treatment options.  In this setting, the available treatments are frequently associated with toxicities, 17 
which may result in these therapies having little to no overall clinical benefit for the individual patient.  18 
For this population, clinical benefit should be determined by assessing changes in symptoms that are 19 
known to predict morbidity and mortality. In this study, novel objective response criteria has been used 20 
to establish the efficacy of MABp1, thus providing a potential blueprint for development of a new class 21 
of agents that selectively target the disease pathophysiology.  22 
 23 
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Figure 1.  Response Flow Chart 1 
 2 The primary endpoint of the study was a comparison of response rates between MABp1 3 monotherapy and placebo arms. Response criteria included DEXA measure of lean body mass 4 (LBM) and patient self-reported assessment of health status using the EORTC-QLQ-C30 5 questionnaire. From baseline to the 8-week study endpoint, a subject was considered to have 6 achieved a response if they were found to have stable or increased lean body mass, and stable or 7 improved symptoms in two-out-of-three of the categories of pain, fatigue and anorexia. Patients in 8 either the treatment or placebo arms could therefore qualify as responders. Responder analysis 9 therefore was a measure of either clinical progression or improvement of individuals across study 10 arms. 11 
 25 
Figure 2. Disposition of Patients 1 
 2 
A total of 458 patients were screened and 333 randomized. Three-hundred and nine patients received 3 
at least one dose of therapy between May 20th, 2014 to November 3rd, 2015. A total of 202 patients 4 
continued in the open label phase of the study and received the active therapy. This included 140 5 
(68%) of 207 patients from treatment and 62 (61%) of 102 patients from placebo arms. 6 
 7 
 8 
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Table 1 Demographic and Other Baseline Characteristics (mITT) 1 
  
Treatment Group 
Total 
(N= 309) MABp1+BSC  
(N= 207) 
Placebo+BSC  
(N=102) 
Age, year       
      Mean 63±10 63±9 63±10 
      Median 64 63 63 
      Min-Max 31-83 38-84 31-84 
Age distribution, n(%)       
      <65 years 112 (54%) 60 (59%) 172 (56%) 
      ≥65 to <75 years 72 (35%) 32 (31%) 104 (34%) 
      >75 years  23 (11%) 10 (10%) 33 (11%) 
Sex, n(%)       
      Female 79 (38) 43 (42) 122 (39) 
*Race, n(%)       
      White 202 (98) 101 (99) 303 (98) 
      Asian  2 (1) 0 2 (1) 
Geographic Region, n(%)       
      EU 176 (85) 91 (89) 267 (86) 
      Georgia 15 (7) 4 (4) 19 (6) 
      Russia 16 (8) 7 (7) 23 (7) 
*KRAS Mutation Status, n(%)       
      KRAS Mutation 85 (41%) 37 (36) 122 (39) 
      KRAS wild-type 91 (44%) 56 (55) 147 (48) 
      Test Not Done 30 (14%) 9 (9) 39 (13) 
ECOG Performance Status       
      1 170 (82%) 80 (78) 250 (81) 
      2 37 (18%) 22 (22) 59 (19) 
 Days on Study 48±9   49±10  49±9 
Baseline Weight, kg       
      Mean 74±20 76±16 75±18 
      Median 72 75 74 
      Min-Max 36-172 43-154 36-172 
Baseline Serum IL-6    
      Median (pcg/ml) 9.9 (4.6-28) 9.8 (4.3-25)  
Histology, n(%)       
      Adenocarcinoma 204 (99%) 100 (98) 304 (98) 
      Adenocarcinoma in situ 1 (0%) 1 (1) 2 (1) 
      Other 2 (1%) 1 (1) 3 (1) 
Number of prior chemotherapy regimens for 
metastatic disease, n(%)       
 27 
  
Treatment Group 
Total 
(N= 309) MABp1+BSC  
(N= 207) 
Placebo+BSC  
(N=102) 
      2 55 (27) 29 (28) 84 (27) 
      3 56 (27) 33 (32) 89 (29) 
      4 42 (20) 21 (21) 63 (20) 
      5 23 (11) 7 (7) 30 (10) 
      ≥6 27 (13) 12 (12) 39 (13) 
Abbreviation: ECOG= Eastern Cooperative Oncology Group 1 
• Race was missing for 4 patients and KRAS Mutation Status was missing for one patent 2 
 3 
Table 2: Results of CRR Primary Analysis  4 
 MABp1+BSC  Placebo+BSC  
N 207 102 
Clinical Response, n (%) 68 (33%) 19 (19%) 
Difference (effect size) 14% 
P value from Pearson Chi-Square test 
(one-tailed) 0.0045 
Relative Risk (95% CI) 1.76 (1.12, 2.77) 
 5 
 6 
 7 
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 12 
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Table 3: Sensitivity Analysis of the Response Rate 1 
Sensitivity 
Analysis 
Xilonix+BSC  Placebo+BSC  Difference  
(effect 
size) 
*P value  
(Pearson 
Chi-Square 
test)  
Relative Risk  
(95% CI) 
N CRR, 
 n (%) 
N CRR, 
 n (%) 
ECOG 1 170 57 (34%) 80 16 (20%) 14% 0.014 1.68 (1.03, 2.73) 
ECOG 2 37 11 (30%) 22 3 (14%) 16% 0.14 2.18 (0.68, 6.97) 
Female 79 24 (30%) 43 3 (7%) 23% 0.002 4.35 (1.39, 13.63) 
Male 128 44 (34%) 59 16 (27%) 7% 0.162 1.27 (0.78, 2.05) 
KRAS Wild-Type 85 30 (35%) 37 6 (16%) 19% 0.02 2.18 (0.99, 4.78) 
KRAS Mutation 91 26 (29%) 56 10 (18%) 11% 0.07 1.60 (0.84, 3.06) 
CRR: clinical response rate, ECOG: Eastern Cooperative Oncology Group 2 
The primary endpoint was subjected to sensitivity analysis. Responders were stratified by ECOG status, 3 
gender, geography and KRAS mutation status. Such stratification has limitations with the relatively 4 
small sample population of the study. The results were nevertheless considered consistent with the 5 
primary endpoint analysis. 6 
 7 
Table 4: Comparison of Pharmacodynamic Outcomes between Treatment arm and 8 
Placebo 9 
Change in Self-Reported Outcomes and 
Pharmcodynamic Measures from Baseline to 8 Weeks 
LS Mean±Standard Error 
P (LS mean 
difference) Placebo+BSC (n=102) Xilonix+BSC (n=207) 
Serum IL-6 Levels* (pg/mL) 9.90±2.71 1.6±1.9 0.012 
Platelet Count (1000/mm3) 40±8 14±5 0.0052 
Global QOL (Score) -4.03±2.27 -2.36±1.58 0.547 
Physical Function (Score) -3.38±2.19 -5.11±1.53 0.5183 
Role Function (Score) -7.83±3.02 -6.83±2.12 0.786 
Emotional Function (Score) 1.37±2.34 2.50±1.64 0.692 
Social Function (Score) 0.00±3.06 -0.89±2.14 0.811 
*Four observations with extreme value were removed.  10 
 29 
Individual analysis of EORTC and DEXA measures alone revealed significant differences between 1 
arms. Comparison between arms for pharmacodynamic measures shows a significant reduction in 2 
serum IL-6 levels and in thrombocytosis. There was no difference in self-reported measures between 3 
arms. These findings confirm that the combined primary endpoint were critical to measuring response 4 
to therapy. 5 
 6 
Table 5: Post Hoc Analysis, Comparing Individual Elements of the Primary Endpoint by Arm 7 
Outcome Measures  
Xilonix+BSC 
(N=207) 
Placebo+BSC 
(N=102) 
Difference  
(effect size) 
P value  
(1-sided 
Pearson Chi-
Square test)  
Relative Risk  
(95% CI) 
Objective Response, 
 n (%) 
Objective Response, 
 n (%) 
LBM Response 105 (51%) 46 (45%) 6% 0.18 1.11 (0.89, 1.39) 
Pain  93 (45%) 45 (44%) 1% 0.45 1.01 (0.82, 1.25) 
Fatigue 94 (45%) 46 (45%) 0% 0.48 1.0 (0.81, 1.25) 
Appetite 114 (55%) 49 (48%) 7% 0.12 1.16 (0.91, 1.47) 
Post hoc analysis was performed for individual measures of the combined primary endpoint. Each of 8 
the composite measures were individually analyzed to assess possible differences between arms. No 9 
individual measures were found to be different between arms. These findings confirm that the 10 
combined primary endpoint was a more relevant readout than any of the component measures with 11 
respect to therapeutic activity of the antibody.  12 
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Table 6. Post Hoc Analysis to Assess Change for Individual Measures of Self-Reported and Pharmacodynamic 1 
Outcomes  2 
  
LS Mean±Standard Error 
P value  
Non-responder  Responder 
Change in Lean Body Mass (kg) 0.072±0.22 1.41±0.30 0.00044 
Change in Global QoL (Score) -6.98±1.56 4.32±2.08 <0.0001 
Change in Physical Function (Score) -9.85±1.49 4.12±1.91 <0.0001 
Change in Role functioning (Score) -13.43±2.08 3.87±2.77 <0.0001 
Change in Emotional functioning (Score) -2.33±1.61 10.03±2.15 <0.0001 
Change in Social functioning (Score) -6.71±2.11 10.16±2.81 <0.0001 
Change in Platelet Count (x1000/mm3) 33.3±5.2 -2.0±0.79 <0.00017 
Change in IL-6 (pg/mL) 10.3±2.2 -3.38±6.31 0.00071 
Change in Fatigue (Score)  10.81±1.81 -8.35±2.42 <0.0001 
Change in Pain (Score)  13.70±2.07 -10.01±2.75 <0.0001 
Change in Appetite, Score 14.46±2.33 -9.83±3.11 <0.0001 
Incidence of Serious Adverse Events 29.3% (65 of 222) 5.7% (5 of 87) <0.0001 
Incidence of Stable Disease 11.7% (26 of 222) 24.1% (21 of 87) 0.0062 
 3 
Individual components of the primary endpoint, as well as all other outcomes, were assessed with 4 
respect to the primary endpoint. Each of these measures were positively correlated with the 5 
prospectively defined response. Individual measures of the primary endpoint showed not just 6 
stabilization but significant improvement, including gain in lean body mass (1.41±0.30kg (p0.00044); 7 
and  reductions in fatigue (-8.35±2.42; p<0.0001), pain (-10.01±2.75; p<0.0001) and anorexia (-8 
9.83±3.11p<0.0001). An increase in EORTC scores indicates improvement, except that a reduction in 9 
scores for pain, appetite, and fatigue represent improvement. Least-square mean (LSM), computed by 10 
fitting analysis of covariance (ANCOVA) model with overall response status as factor and baseline 11 
value as covariate.  12 
 13 
 14 
 15 
 16 
 17 
 18 
 31 
Table 7.  Adverse Events (>10%) Occurring During the 8 Week Period 1 
  Xilonix, n=207 Placebo, n=102 
AE Preferred 
Term Grade I/II Grade III 
Grade 
IV 
Grade 
V Total Grade I/II Grade III 
Grade 
IV Grade V Total 
Abdominal 
pain 31 (15.0%) 5 (2.4%)     36 (17.4%) 10 (9.8%) 2 (2.0%)     12 (11.8%) 
Fatigue 21 (10.1%) 6 (2.9%)     27 (13.0%) 6 (5.9%) 7 (6.9%)     13 (12.7%) 
Oedema 
peripheral* 24 (11.6%) 4 (1.9%)     28 (13.5%) 5 (4.9%) 2 (2.0%)     7 (6.9%) 
Anaemia 13 (6.3%) 8 (3.9%)     21 (10.1%) 2 (2.0%) 5 (4.9%)   1 (1.0%) 8 (7.8%) 
Weight 
decreased 21 (10.1%)       21 (10.1%) 8 (7.8%)       8 (7.8%) 
Constipation 21 (10.1%)       21 (10.1%) 6 (5.9%)       6 (5.9%) 
Asthenia 17 (8.2%) 2 (1.0%)     19 (9.2%) 7 (6.9%) 3 (2.9%)     10 (9.8%) 
Nausea 18 (8.7%)       18 (8.7%) 11 (10.8%) 1 (1.0%)     12 (11.8%) *Fluid overload in the form of peripheral edema or ascites could potentially confound the assessment of lean body mass as 2 measured by DEXA.  However, the composite endpoint was intended to correct for this potential confounder.  Only 2.9% of 3 responders in the MABp1 arm (2 of 68) and 5.3% (1 of 19) responders in the placebo had developed evidence of fluid overload 4 (edema or ascites) at the week 8 assessment. 5 
 6 
 7  8 
 9 
 10 
 11 
 12 
 13 
 14 
  15 
 32 
References 1                                                         
1 Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet 2012;380: 2095e128. 
 
2 Obrand DI, Gordon PH.  Incidence and patterns of recurrence following curative resection for colorectal carcinoma.  Dis Colon Rectum. 1997 
Jan;40(1):15-24. 
 
3 Guideline on the evaluation of anticancer medicinal products in man, 13 December 2012.  EMA/CHMP/205/95/Rev.4.  Oncology Working 
Party 
 
4 Dinarello CA.  Interleukin-1α neutralisation in patients with cancer.  Lancet Oncol. 2014 May;15(6):552-3. doi: 10.1016/S1470-
2045(14)70164-0. Epub 2014 Apr 17. 
 
5 Tjomsland V, et al.  Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting 
cancer-associated fibroblasts.  Neoplasia. 2011 Aug;13(8):664-75. 
 
6 Tomimatsu S, Ichikura T, Mochizuki H.  Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric 
carcinoma.  Cancer. 2001 Apr 1;91(7):1272-6. 
 
7 Ricote et al. Interleukin-1 (IL-1α and IL-1b) and Its Receptors (IL-R1, IL-RII and IL-1Ra) in Prostate Carcinoma. Cancer 2004;100:1388-96. 
 
8 Miller LJ, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000;18:293–302. 
9 Voronov et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003 March 4; 100 (5): 2645–2650 
 
10 Salven et al. Interleukin-1α promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and 
secretion. FASEB J. 2002 July 18; 1471-73. 
 
11 Apte et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 
2006 Sep;25(3):387-408. 
 
12 Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. 
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.  Invest New Drugs. 
2015 Jun;33(3):621-31. doi: 10.1007/s10637-015-0226-6. Epub 2015 Mar 31. 
 
13 Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard 
J, Kurzrock R.  MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-
escalation and expansion study.  Lancet Oncol. 2014 May;15(6):656-66. doi: 10.1016/S1470-2045(14)70155-X. Epub 2014 Apr 17. 
 
14 Yeh KY, Li YY, Hsieh LL, et al.  Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients 
with colorectal cancer.  Jpn J Clin Oncol. 2010 Jun;40(6):580-7. doi: 10.1093/jjco/hyq010. Epub 2010 Mar 1. 
 
15 Stone RL, Nick AM, McNeish IA, et al.  Paraneoplastic thrombocytosis in ovarian cancer.  N Engl J Med. 2012 Feb 16;366(7):610-8. doi: 
10.1056/NEJMoa1110352. 
 
16 Quinten C, Coens C, Mauer M, et al.  Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data 
from EORTC clinical trials.  Lancet Oncol. 2009 Sep;10(9):865-71. doi: 10.1016/S1470-2045(09)70200-1. Epub 2009 Aug 18. 
 
17 Wallengren O., Lundholm K., Bosaeus I.  Diagnostic Criteria of Cancer Cachexia:  Relation to Quality of Life, Exercise Capacity, and 
Survival in Unselected Palliative Care Patients.  Support Care Cancer.  2013; 21:1569-1577. 
 
18 Jonker DJ, O'Callaghan CJ, Karapetis CS, et al.  Cetuximab for the treatment of colorectal cancer.  N Engl J Med. 2007 Nov 
15;357(20):2040-8. 
 
19 International Atomic Energy Agency, Human Health Series No. 15.  “Dual Energy X Ray Absorptiometry for Bone Mineral Density and Body 
Composition Assessment”.  http://www.iaea.org/Publications/index.html 
 
20 Toombs R.J., Ducher G., Shepherd J.A., and De Souza M.  The Impact of Recent Technological Advances on the Trueness and Precision 
of DXA to Assess Body Composition.  Obesity (2012) 20, 30–39. 
 
21 Tukey JW, Exploratory Data Analysis. Addison-Wesley, 1977, 43-44. 
22 Rajiput and Wilber. Roles of inflammation in cancer initiation, progression and metastasis. Front Biosci. 20102:176-83. 
23 Terzic et al. Inflammation and colon cancer. Gatroenterology. 2010 138(6):2101-2114. 
24 Gao et al. Role of inflammation-associated microenvironment in tumorigenesis and metastasis. Curr Cancer Drug Targets. 2014. 
14(1):30-45.  
 33 
                                                                                                                                                                                                
25Sophia Ran The role of TLR4 in chemotherapy-driven metastasis. Cancer Res. 2015. 75(12): 2405–2410. 
26 Harrison, C et al. JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine. 
2012 366(9):787-798. 
27 Jager et al. Identification of tumor antigens as potential targets for immunotherapy by serological expression cloning. Cancer Immunol 
Immunother. 2004 53(3):144-7 
28 Turano and Caruso. The role of human autoantibodies against gamma-interferon. Journal of Antimicrobial Chemotherapy. 1993. 32, Suppl. 
A, 99-105 
29 Shapir and Shoenfeld. Facing the Enigma of Immunomodulatory Effects of Intravenous Immunoglobulin.  
30 Shi et al. Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic 
Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. J 
Clin Oncol 2015 33:22-28  
31 Singel and Segal. Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. 2016 Immunol Rev. 
273(1):329-43. 
32 Daenen et al. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. 2011 Cancer Res; 71(22) 6976-
6985. 
 
